Copyright
©The Author(s) 2020.
World J Gastroenterol. Sep 21, 2020; 26(35): 5328-5342
Published online Sep 21, 2020. doi: 10.3748/wjg.v26.i35.5328
Published online Sep 21, 2020. doi: 10.3748/wjg.v26.i35.5328
Figure 5 Rescue experiments of RBBP4.
A: SW620 and HCT116 cells with RBBP4 siRNA or negative control transfection were incubated with or without 20 mmol/L LiCl, then the level of β-catenin in the nucleus was detected by western blotting; B: The viability of SW620 cells with RBBP4 siRNA or negative control transfection cultured in medium with or without 20 mmol/L LiCl; C: The viability of HCT116 cells with RBBP4 siRNA or negative control transfection cultured in medium with or without 20 mmol/L LiCl; D: Invasion of SW620 and HCT116 cells with RBBP4 siRNA or negative control transfection cultured in medium with or without 20 mmol/L LiCl; E: The protein expression of E-cadherin and vimentin in SW620 and HCT116 cells with RBBP4 siRNA or negative control transfection cultured in medium with or without 20 mmol/L LiCl. bP < 0.01 vs controls.
- Citation: Li YD, Lv Z, Zhu WF. RBBP4 promotes colon cancer malignant progression via regulating Wnt/β-catenin pathway. World J Gastroenterol 2020; 26(35): 5328-5342
- URL: https://www.wjgnet.com/1007-9327/full/v26/i35/5328.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i35.5328